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Abstract
The efficacy and safety of chidamide, a new subtype-selective histone deacetylase (HDAC) inhibitor, have been
demonstrated in a pivotal phase II clinical trial, and chidamide has been approved by the China Food and Drug
Administration (CFDA) as a treatment for relapsed or refractory peripheral T cell lymphoma (PTCL). This study
sought to further evaluate the real-world utilization of chidamide in 383 relapsed or refractory PTCL patients from
April 2015 to February 2016 in mainland China. For patients receiving chidamide monotherapy (n = 256), the overall
response rate (ORR) and disease control rate (DCR) were 39.06 and 64.45%, respectively. The ORR and DCR were 51.
18 and 74.02%, respectively, for patients receiving chidamide combined with chemotherapy (n = 127). For patients
receiving chidamide monotherapy and chidamide combined with chemotherapy, the median progression-free
survival (PFS) was 129 (95% CI 82 to 194) days for the monotherapy group and 152 (95% CI 93 to 201) days for
the combined therapy group (P = 0.3266). Most adverse events (AEs) were of grade 1 to 2. AEs of grade 3 or higher
that occurred in ≥5% of patients receiving chidamide monotherapy included thrombocytopenia (10.2%) and
neutropenia (6.2%). For patients receiving chidamide combined with chemotherapy, grade 3 to 4 AEs that occurred
in ≥5% of patients included thrombocytopenia (18.1%), neutropenia (12.6%), anemia (7.1%), and fatigue (5.5%).
This large real-world study demonstrates that chidamide has a favorable efficacy and an acceptable safety profile
for refractory and relapsed PTCL patients. Chidamide combined with chemotherapy may be a new treatment
choice for refractory and relapsed PTCL patients but requires further investigation.
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Peripheral T cell lymphomas (PTCLs) are a set of rare
and highly heterogeneous tumors derived from mature
T cells or natural killer cells and are typically character-
ized by poor prognosis and aggressive clinical behavior
[1]. PTCL accounts for 23 to 26% of all non-Hodgkin’s
lymphoma (NHL) in China, which is significantly higher
than the rates in Western countries [2, 3]. A consensus
has not been reached on standard treatments for PTCL
patients, and most commonly used traditional chemo-
therapy regimens are associated with a poor response [1,
4]. Moreover, a majority of patients may experience dis-
ease relapse even if they receive high-dose chemotherapy
and autologous stem cell transplantation (ASCT) [5, 6]
Since 2009, the US Food and Drug Administration
(FDA) has approved four new drugs for the treatment of
relapsed or refractory PTCL, including the histone
deacetylase (HDAC) inhibitors romidepsin and belino-
stat, the dihydrofolate reductase inhibitor pralatrexate,
and the CD30 antibody-drug conjugate brentuximab
vedotin for CD30-positive anaplastic large cell lymph-
oma (ALCL) patients [7, 8].
Chidamide, an innovative new drug independently
developed in China, is designed to selectively inhibit the
activity of HDAC1, 2, 3, and 10 following oral adminis-
tration and was approved in December 2014 by the
China Food and Drug Administration (CFDA) for the
treatment of relapsed or refractory PTCL [9].
The efficacy and safety of chidamide have been dem-
onstrated in a pivotal phase II clinical trial [10], yet fur-
ther evaluation of its real-world utility is urgently
needed. Therefore, we conducted a real-world multicen-
ter efficacy and safety monitoring study to further test
the clinical practice value of chidamide in relapsed or
refractory PTCL patients in mainland China.
We analyzed 383 patients from April 2015 to February
2016. The cutoff date was February 19, 2016. The
methods are shown in Additional file 1. The baseline char-
acteristics of all patients are presented in Additional file 2.
For patients receiving chidamide monotherapy (n =
256), the overall response rate (ORR) and disease control
rate (DCR) were 39.06 and 64.45%, respectively. In pre-
vious phase II study, the AITL patients received chida-
mide have a higher ORR of 50%. Higher ORR and
superior survival were also observed for AITL patients
received romidepsin and belinostat. In this real world
study, AITL patients also tend to have higher ORR and
DCR of 49.23% and 75.38% which were comparable with
previous results. It has been reported that epigenetic
regulation plays an important role in AITL pathogenesis,
which may be relevant to more clinical benefits by
HDAC inhibitors to AITL. The ORR and DCR seem
higher for ALK+ ALCL patients receiving chidamide of
66.67% and 83.33%, but only 13 ALK+ ALCL patients
receiving chidamide were included in this study and
ALK+ ALCL alone has a better prognosis than other
subtypes. Given that HDAC inhibitors can impair DNA
repair mechanisms, thereby inducing DNA damage, the
effects of HDAC inhibitors may be synergistic with the
effects of chemotherapy. Several studies have shown that
HDAC inhibitors combined with chemotherapy consti-
tute an efficient treatment for PTCL patients, yet the
optimal combination regimen remains unknown. This
study found that the ORR and DCR were 51.18 and
74.02%, respectively, for patients receiving chidamide
combined with chemotherapy (n = 127). For patients
with an International Prognostic Index (IPI) of 2–3, the
ORR in the chidamide combined with chemotherapy
group (n = 55) was 58% higher than that in the chida-
mide single-agent group (n = 141), with an ORR of 41%
(P = 0.0031). Chidamide combined with chemotherapy
also increased the ORR for patients with an IPI of 4–5
(n = 26) relative to the ORR of patients receiving chida-
mide alone (n = 40) with ORRs of 42 and 10%, respect-
ively (P = 0.006). The results of a subgroup analysis
showed that the ORRs for patients receiving chidamide
combined with cyclophosphamide, doxorubicin, vincris-
tine, and prednisone (CHOP)-like regimens, platinum-
containing regimens, and other regimens were 53.13,
45.83, and 55.32%, respectively, with DCRs of 81.25,
66.67, and 76.60%, respectively (Table 1).
For patients receiving chidamide monotherapy and
chidamide combined with chemotherapy, the median
progression-free survival (PFS) was 129 (95% CI 82 to
194) days and 152 (95% CI 93 to 201) days, respectively
(P = 0.3266) (Fig. 1) and the median duration of response
(DOR) was 148 (95% CI 132 to 171) days and 169 (95%
CI 154 to 192) days, respectively (P = 0.3215). In the
chidamide monotherapy group, the PFS for AITL and
peripheral T cell lymphoma-not otherwise specified
(PTCL-NOS) patients were 144.5 days and 133 days,
respectively. In the combination group, the PFS for
AITL and PTCL-NOS patients were 176 days and
124 days, respectively. The results of a subgroup analysis
showed that the median PFS for patients receiving
chidamide combined with CHOP-like regimens,
platinum-containing regimens, and other regimens was
172, 119, and 160 days, respectively. The median DOR
for patients receiving chidamide combined with CHOP-
like regimens, platinum-containing regimens, and other
regimens was 180, 165, and 172 days, respectively.
Drug-related adverse events (AEs) that occurred in
≥5% of patients receiving chidamide alone included
thrombocytopenia (25.0%), neutropenia (19.1%), fatigue
(18.4%), nausea/vomiting (14.1%), and anemia (11.3%).
Drug-related AEs that occurred in ≥5% of patients re-
ceiving chidamide combined with chemotherapy in-
cluded thrombocytopenia (28.4%), neutropenia (25.2%),
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fatigue (24.4%), anemia (17.3%), nausea/vomiting
(12.7%), increased alanine aminotransferase (ALT)
(9.5%), and increased aspartate aminotransferase (AST)
(6.3%). Most AEs were of grade 1 to 2. AEs of grade 3 or
higher that occurred in ≥5% of patients receiving chida-
mide alone included thrombocytopenia (10.2%) and neu-
tropenia (6.2%). For patients receiving chidamide
combined with chemotherapy, grade 3 to 4 AEs that oc-
curred in ≥5% of patients included thrombocytopenia
(18.1%), neutropenia (12.6%), anemia (7.1%), and fatigue
(5.5%) (Additional file 3).
In summary, this real-world study conducted with
383 patients demonstrates that chidamide has a favor-
able efficacy and an acceptable safety profile for
refractory and relapsed PTCL patients, confirming the
pivotal phase II study in a more representative real-
world population. Moreover, this study indicated the
potential benefit of chidamide when combined with
chemotherapy, which had not been previously exam-
ined. Chidamide combined with chemotherapy may
be a new treatment choice for PTCL, especially for
PTCL patients with an IPI ≥2, although further inves-
tigation is warranted.
Additional files
Additional file 1: Methods (DOCX 16 kb)
Additional file 2: Table S1. Patients’ baseline characteristics (DOCX 16 kb)
Additional file 3: Table S2. Drug-related adverse events in ≥5% of
patients (DOCX 21 kb)
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